Dyne Therapeutics, Inc. Common Stock (DYN) Stock Price
DYNStock
$26.34+106.60%52W
Market Cap$4.92B
P/E—
PEG Ratio—
Div yield—
Beta1.10
DYN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)57.74%
Price vs S&P 500 (4W)-2.70%
VGM Score79.92
DYN Earnings Surprise History
Q2 25-0.97est. -0.93
Q3 25-0.76est. -0.85
Q4 25-0.73est. -0.76
Q1 26-0.73est. -0.78
Q2 26-1.08est. -0.75
DYN Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.20
4.20
4.19
4.24
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DYNDyne Therapeutics, Inc. Common Stock | — | — | B | $26.34 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Dyne Therapeutics, Inc. Common Stock
Dyne Therapeutics is a clinical-stage biopharmaceutical company developing treatments for genetically driven neuromuscular diseases. Its proprietary FORCE platform addresses a critical delivery challenge to muscle tissue and the central nervous system that limits existing therapies. The company has multiple programs in clinical development targeting distinct neuromuscular indications.